Skip to main content
Category

News Archive

dna-genes-pixa

Money Behind First CRISPR Test? It’s from Internet Billionaire Sean Parker

By News Archive

dna-genes-pixa

The first proposed test of CRISPR gene-editing technology in human beings is being funded by Internet billionaire Sean Parker, MIT Technology Review has learned.

The novel cancer treatment, initially disclosed last week, is being reviewed Tuesday by a federal advisory panel in Washington, D.C., and could become the first clinical trial involving CRISPR, the red-hot gene modification technology.

Read More
emergent-biosolution-logo

FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

By News Archive

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55, the company’s large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.

Read More
disease-heart-health-pixa

Predicting Contagiousness to Limit the Spread of Disease

By News Archive

disease-heart-health-pixa

Imagine the workplace during flu season. Some people get sick and display clear symptoms—a warning sign to coworkers to avoid contact and for that individual to stay home. Others are infected, but never or only belatedly exhibit the tell-tale signs of sickness, meaning they can infect coworkers without knowing it. If healthcare professionals had the ability to test in advance whether a person is likely to spread a disease following infection, they could recommend specific measures to treat the person or limit exposure and perhaps keep an outbreak from growing into an epidemic or pandemic.

Read More
laboratory-blood-work-biotech-pixa

Biotech is booming – Cambridge News

By News Archive

laboratory-blood-work-biotech-pixa

The UK biotechnology sector continues to build on the success of previous years, raising an unprecedented £900m on the London Stock Exchange in 2015 and recording the highest level of venture finance in recent years, according to the latest report Money, momentum and maturity: UK biotech financing and deals in 2015/16 compiled by the UK BioIndustry Association (BIA) in partnership with Evaluate and the London Stock Exchange.

Read More
martin-omalley-gov-image

Do cities need a point-person to lead innovation?

By News Archive

martin-omalley-gov-image

As cities continue to invest more in smart city technologies, questions surrounding how to staff those moves can puzzle city leaders.

Martin O’Malley, the former mayor of Baltimore and governor of Maryland, suggested during remarks at the Smart Cities Innovation Summit that during his leadership — both at the city and state levels — having a chief innovation officer close to the executive was key to driving government away from the status quo and into new possibilities.

Read More
emergent-biosolution-logo

Emergent BioSolutions: Underlying Value To Be Realized Following Aptevo Spin-Off – Seeking Alpha

By News Archive

emergent-biosolution-logo

Emergent BioSolutions Inc. is a global specialty pharmaceutical company, which offers specialized products to governments and healthcare providers. The company derives most of its revenue from one product, BioThrax, which is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, about 56% of the company’s revenue came from the sale of BioThrax with the remainder coming from the sale of their other biodefense products, biosciences products, and contract manufacturing.

Read More
Alexandria-Real-Estate-Equities-Logo

Alexandria Real Estate Equities launches co-working for science guys – Real Estate Weekly

By News Archive

Alexandria-Real-Estate-Equities-Logo

Alexandria Real Estate Equities, the owner and developer of the Alexandria Center for Life Science on the East Side of Manhattan, has just launched an incubator space for biotech start-ups.

The new life science laboratory and office platform, which will be called Alexandria Launchlabs, promises 15,000 s/f of space that provides “the necessary resources and collaborative environment to start transforming novel ideas into innovative, early-stage companies that develop products to improve human health.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.